arrow
C

Carolyn S.P. Lam

National University of Singapore
H指数:128
被引数:9.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial

米替哌stat抑制髓过氧化物酶在射血分数保留或轻度降低的心力衰竭中的应用:一项随机2b期试验

2026-09-090
PRE
Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis

在有无癌症病史的心肾代谢综合征患者中非奈利酮的获益:FINE-HEART合并分析

2026-08-180
OAAI
Clinical characteristics, treatment patterns, and costs among hospitalised patients with cardiomyopathy: a multicentre retrospective tertiary-hospital study across China

中国多中心三级医院回顾性研究:住院心肌病患者的临床特征、治疗模式及费用

2026-08-080
OA
Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy on CKD progression

ZENITH高蛋白尿试验的设计和基线特征:评估zibotentan/dapagliflozin对CKD进展有效性的研究

2026-08-040
OAAI
Chronic obstructive pulmonary disease and risk of incident cardiovascular disease, chronic kidney disease, and death: a systematic review and meta-analysis

慢性阻塞性肺疾病与心血管疾病、慢性肾脏疾病发病风险及死亡风险:一项系统评价和荟萃分析

2026-08-012
OAAI
Prevalence and predictors of high inflammatory risk in heart failure subtypes: findings from the global POSEIDON study

心衰亚型中高炎症风险的发生率及其预测因素:全球POSEIDON研究的结果

2026-01-010
OA
The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial

维利西呱对心脏性猝死的影响:VICTOR试验的见解

2026-01-010
OA
Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial

布地奈德/格隆溴铵/富马酸福莫特罗二水合物对COPD患者心肺结局的影响: THARROS试验的原理和设计

2025-12-221
PRE
Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Finerenone相关的低血压风险:在轻度降低或保留射血分数的心力衰竭中

2025-12-090
OAAI
Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis

基于人工智能的心脏超声评估在监测甲状腺素转运蛋白心脏淀粉样变性疾病进展中的应用

2025-10-160
OAAI
Obese HFpEF

肥胖HFpEF

JACC
IF0
2025-10-130
PRE
Sex differences in NT-proBNP associations with risk of heart failure subtypes and response to an intensive lifestyle intervention in type 2 diabetes and overweight or obesity: a post-hoc analysis of the Look AHEAD trial

NT-proBNP与心力衰竭亚型风险及对强化生活方式干预的反应在2型糖尿病和超重或肥胖中的性别差异:Look AHEAD试验的事后分析

2025-10-060
PRE
Lifetime Benefits of Comprehensive Medical Therapy in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

轻度或保留射血分数心力衰竭患者综合药物治疗的全生命周期获益

2025-10-060
PRE
Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT-HF registry

急性心力衰竭住院后的多药联用全球模式:来自REPORT-HF注册研究的患病率与结局

2025-10-011
OAAI